Phaseline

Companies › VistaGen Therapeutics

VistaGen Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fasedienol Nasal Spray–Phase 3Social Anxiety Disorder; Social Anxiety Disorder (SAD)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06358651Fasedienol Nasal SprayPhase 3Social Anxiety DisorderPsychiatryOct 2025
NCT06615557Fasedienol Nasal SprayPhase 3Social Anxiety Disorder (SAD)PsychiatryApr 2026
NCT06809179Fasedienol Nasal SprayPhase 2Social Anxiety DisorderPsychiatryJun 2026

From the company's SEC filings

Cash and short-term investments of $32m on 2026-06-30; operating cash outflow about $60m a year; runway about 6 months at that burn, to Jan 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Reviva Pharmaceuticals Curemark Emalex Biosciences Boston Medical Group Transcend Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.